New Parkinson's drug passes first safety check in small trial
NCT ID NCT06659562
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 32 times
Summary
This early-phase study tested a new drug called HER-096 in 32 people to see if it is safe and how the body processes it. Healthy volunteers received a single dose, while Parkinson's patients received multiple doses over 4 weeks. The goal was to check for side effects and measure drug levels, not to prove it works as a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE, IDIOPATHIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Services Turku - CRST Oy
Turku, Finland, Finland
Conditions
Explore the condition pages connected to this study.